Stock price performance of Keryx Biopharmaceuticals, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -14.71% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 24.71% . Looking at the past 52 week period, the stock price is up at 53.52% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Keryx Biopharmaceuticals, Inc. has a positive value of 25.48 compared to overall market. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 17.44% and the 50-Day Moving Average is 18.49%.The 200 Day SMA reached 13.3%
Keryx Biopharmaceuticals, Inc. is having a Relative Strength Index of 49.82 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rallied by 13.54% during the past week but lost 10.07% on a 4-week basis. The company has outperformed the S&P 500 by 13.41% in the past week but underperformed the index by 10.87% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Jan 31, 2017, Scott A Holmes (Chief Financial Officer) sold 8,447 shares at 4.65 per share price.On Jan 31, 2017, John F. Neylan (Chief Medical Officer) sold 6,984 shares at 4.65 per share price.On Jan 31, 2017, Greg Madison (President and CEO) sold 18,248 shares at 4.65 per share price.
Keryx Biopharmaceuticals Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.19. Analyst had a consensus of $-0.20. The company had revenue of $6.30 million for the quarter, compared to analysts expectations of $5.53 million. The companys revenue was up 50.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Keryx Biopharmaceuticals was Upgraded by Citigroup to Neutral on Jan 11, 2017. Keryx Biopharmaceuticals was Upgraded by Maxim Group on Nov 9, 2016 to Buy, Price Target of the shares are set at $7.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.03 points or 0.55% at $5.45 with 1,540,995 shares getting traded. Post opening the session at $5.51, the shares hit an intraday low of $5.22 and an intraday high of $5.55 and the price was in this range throughout the day. The company has a market cap of $577 million and the number of outstanding shares has been calculated to be 105,960,364 shares. The 52-week high of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is $7.8 and the 52-week low is $3.11.
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.